摘要
目的分析CHOP化疗方案对外周T细胞淋巴瘤-非特指型(PTCL-U)患者近期疗效及远期生存的作用,并探讨其可能的影响因素。方法回顾性分析68例PTCL-U患者的临床资料,采用Kaplan-Meier法分析患者治疗后的生存率及CHOP方案单纯化疗与该方案联合放疗对PTCL-U患者的影响,用单因素分析及Cox比例风险回归模型分析影响患者生存的可能因素。结果 68例PTCL-U患者治疗完全缓解(CR)率为28%,5年生存率为25.63%,初治疗效达到CR的患者生存率明显提高;单纯化疗与化疗联合放疗的5年生存率分别为19.4%、37.1%,化疗联合放疗的远期生存率优于单纯化疗,差异有统计学意义(P<0.05)。治疗前体力状况(PS)评分、治疗疗效及骨髓是否受侵是影响生存的独立因素。结论采用CHOP方案治疗PTCL-U患者近期疗效较高,但远期生存率较低;初治疗效获得CR、化疗联合放疗可提高患者生存率。
Objective To analyze the short-term efficacy and long-term survival of CHOP regimen on peripheral T-cell lymphoma-unspecified（PTCL-U） patients and explore the possible influencing factors.Methods Clinical materials of 68 PTCL-U patients were analyzed.That survival rate and the influencing factors of patients treated with chemotherapy and chemotherapy combined with radiotherapy were analyzed by Kaplan-Meier analysis.The possible influencing factors of survival were analyzed by single factor analysis and the Cox proportional hazards regression model.Results Complete remission（CR） rate of 68 PTCL-U patients was 28%.5-year survival rate was 25.63%.The survival of patients had been improved for initial treatment with CR.Chemotherapy combined with radiotherapy in long-term survival rate was significantly superior to chemotherapy alone（P0.05）.PS score before treatment,curative effect and bone marrow invasion were the independent factors which affected quality of life.Conclusion CHOP regimen has higher curative effect and lower long-term survival rate in PTCL-U patients.Initial treatment with CR and chemotherapy combined with radiotherapy can improve patient survival.
出处
《安徽医科大学学报》
CAS
北大核心
2011年第7期686-689,共4页
Acta Universitatis Medicinalis Anhui
关键词
淋巴瘤
T细胞
外周
抗肿瘤联合化疗方案
综合疗法
lymphoma
T-cell
peripheral
antineoplastic combined chemotherapy protocols
combined modality therapy
